This network meta-analysis demonstrates that antiangiogenic combinations improve outcomes in driver-negative advanced NSCLC. Endostar + chemotherapy offers the greatest OS benefit, atezolizumab-bevacizumab-chemotherapy improves ORR, and sintilimab-anlotinib provides superior PFS with lower toxicity. Treatment should be tailored based on clinical factors, with further validation in multiethnic trials.
Li et al. (Wed,) studied this question.